Private biotech sits apart from traditional venture capital and growth equity for three key reasons. First, the potential for value creation is driven by clinical inflection points (scientific derisking) instead of revenue growth or operating scale. Second, outcomes at key readouts are often binary rather than incremental, producing wider dispersion. ...